@article{TCR25233,
author = {Jose A. Carrillo and Santosh Kesari},
title = {Is re-radiation for glioblastoma after progression associated with increased survival: to treat or not to treat?},
journal = {Translational Cancer Research},
volume = {8},
number = {1},
year = {2018},
keywords = {},
abstract = {Glioblastoma is the most common malignant brain tumor, representing 53.8% of all gliomas (1). Despite standard of care treatment with radiation and temozolomide chemotherapy, glioblastoma has a dismal prognosis with median survival of 14.6 months (2) and 20.9 months with addition of tumor-treating fields (Optune) (3). After tumor progression, treatment with re-irradiation and/or systemic therapy has yet to show improved overall survival leading to disagreement as to the best management of the patient who has progressed after standard of care treatment.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/25233}
}